CLINICAL TRIALS PROFILE FOR FUSILEV
✉ Email this page to a colleague
All Clinical Trials for FUSILEV
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01789723 ↗ | Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn | Withdrawn | Acrotech Biopharma LLC | Phase 1 | 2013-03-01 | The purpose of this study is determine the optimal dose and schedule of Fusilev to prevent or reduce Mucositis in patients with Non-Hodgkin's Lymphoma receiving Folotyn treatment. |
NCT01789723 ↗ | Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn | Withdrawn | Spectrum Pharmaceuticals, Inc | Phase 1 | 2013-03-01 | The purpose of this study is determine the optimal dose and schedule of Fusilev to prevent or reduce Mucositis in patients with Non-Hodgkin's Lymphoma receiving Folotyn treatment. |
NCT01820091 ↗ | Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn® | Withdrawn | Acrotech Biopharma LLC | Phase 1 | 2013-04-01 | To determine the optimal dose and schedule of Fusilev to prevent or reduce Folotyn-related Grade 3 or higher oral mucositis in patients with Non-Small Cell Lung Cancer. |
NCT01820091 ↗ | Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn® | Withdrawn | Spectrum Pharmaceuticals, Inc | Phase 1 | 2013-04-01 | To determine the optimal dose and schedule of Fusilev to prevent or reduce Folotyn-related Grade 3 or higher oral mucositis in patients with Non-Small Cell Lung Cancer. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FUSILEV
Condition Name
Clinical Trial Locations for FUSILEV
Trials by Country
Clinical Trial Progress for FUSILEV
Clinical Trial Phase
Clinical Trial Sponsors for FUSILEV
Sponsor Name